

Investor Newsletter

Issue **09** 2014



MicroPort Attends Cross-Strait (Fujian) Orthopedic Forum

The fifth cross-Strait (Fujian) Orthopedic Forum, organized by Fujian Medical Association, was held in Xiamen from August 22 to August 24. The congress attracted more than 500 participants, during which around 20 experts held symposiums and nearly 100 orthopedic professionals made academic presentations. Shanghai MicroPort Orthopedics Co (“MicroPort Orthopedics Shanghai”) attended the conference to promote its brand and the SUPERPATH® tissue-preserving hip replacement surgery technique (“SUPERPATH®”) which was well received by the attendance.



MicroPort Attends Chinese Vascular Surgery Congress



From August 21 to August 24, the 12th Chinese Vascular Surgery Congress was held in Shanghai. MicroPort Endovascular (Shanghai) Co (“MicroPort Endovascular”) attended the meeting. On August 23, MicroPort Endovascular hosted a satellite meeting on “the latest development of the treatment of aortic arch diseases” and several reputable experts were invited to deliver speeches.





MicroPort Promote Products in CMEF Regional 2014

From August 29 to August 31, the 15th China Regional Medical Equipment Fair ("CMEF Regional 2014") was held in Suzhou, Jiangsu Province. Shanghai MicroPort Medical (Group) Co ("MicroPort") displayed 37 products in the fair, including devices for cardiovascular, orthopedic, electrophysiological, endovascular, neurovascular, surgical management and diabetes care. We set a special booth to promote our new products, such as Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), WILLIS® Intracranial Stent Graft System ("WILLIS®") and cardiac pacemakers. This fair paves the way for recruiting new regional distributors as we've received 30 letters of intent from distributors.

D-Pulse Gains CE Certificate for PCI Surgical Accessories

D-Pulse Medical (Beijing) Co ("D-Pulse"), MicroPort's wholly-owned subsidiary, gained renewed CE certificate for eight of its independently developed products, including Y-Connector Pack, Pressure Monitoring Tubings, Angiography Syringes, Catheter Introducer Kits and Inflation Device Kits, on September 17. These products are surgical accessories in percutaneous coronary intervention ("PCI") which is used to treat the stenotic or blocked coronary arteries of the heart in coronary heart disease. They are expected to have a promising market with the increasing demand for PCI.

MicroPort Attends Neuro-Intervention Annual Meeting



In mid-September, MicroPort NeuroTech (Shanghai) Co (“MicroPort NeuroTech”) attended Neuro-Intervention Annual Meetings which were held in four places of China - Beijing, Hebei, Henan and Xi’an. During the meetings, doctors of Shanghai East Hospital were invited to explain the clinical applications of MicroPort NeuroTech’s products APOLLO Intracranial Stent System (“APOLLO”) and WILLIS®, which was well received by participated experts. Meanwhile, MicroPort NeuroTech marketing leaders visited some key customers in these regions to further promote sales of APOLLO and WILLIS®.

MicroPort Awarded Shanghai’s High and New Tech Enterprise

On September 5, MicroPort was recognized as one of Shanghai’s High and New Tech Enterprises for 2014.

MicroPort Promotes Surgical Management Devices in Singapore Exhibition

From September 9 to September 12, MicroPort's subsidiary Dongguan Kewei Medical Co ("Dongguan Kewei") attended the 10th International Exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies in Singapore. During the exhibition, several distributors and doctors from Singapore, Thailand, Malaysia and Japan showed interests in Dongguan Kewei's occluders and Membrane Oxygenation System, which paves the way for it to enter in new markets of Singapore as well as the whole Southeast Asia region.



Foxtort NC Awarded Registration in Thailand

On September 11, Foxtort NC Balloon Catheter was awarded registration certificate in Thailand.



MicroPort Reveals Results of Firehawk®'s Clinical Trial

From September 18 to September 21, The 16th Scientific Annual Congress of Chinese Society of Cardiology & The 8th Qianjiang International Cardiovascular Conference was held in Hangzhou of Zhejiang Province. MicroPort attended the meeting. Bo Xu, Director of Intervention Catheter Department with Fuwai Hospital, was invited to deliver a speech on the latest development of Firehawk®'s clinical trial. He noted that the incident rate of thrombosis for Firehawk® stent has so far remained zero according to three-year follow-up results of clinical trials.



Registration Certificates of Thoracolumbar Fusion Cage and Cervical Fusion Cage

On September 18, MicroPort Orthopedics Shanghai gained registration certificates of thoracolumbar fusion cage and cervical fusion cage from Shanghai Food and Drug Administration, valid for five years.



Tonglu Joint Academic Meeting Held

From September 13 to September 14, Tonglu Joint Academic Meeting was held in Tonglu of Zhejiang Province. More than 30 local orthopedic surgeons attended the conference. As the only sponsor, MicroPort helped organize the event and took this opportunity to introduce our orthopedic products to participants. Professor You Wang from the Ninth People's Hospital was invited to deliver speeches about surgical techniques of knee replacement as well as the clinical efficacy of MicroPort's ADVANCE® Knee System.

Guangdong Annual Orthopedic Meeting

MicroPort Orthopedics Shanghai attended the Guangdong Annual Orthopedic Meeting in Guangzhou, Guangdong Province, from September 13 to September 14. During the meeting, we displayed SUPERPATH® surgical technique, instruments and implants, which attracted many distributors and surgeons.

First Sale of MicroPort Sorin

MicroPort Sorin CRM (Shanghai) Co (“MicroPort Sorin”), a joint venture of MicroPort and Sorin Group which was newly founded in May, successfully sold its first batch of pacemakers (a small device that doctors place in people with an abnormal heartbeat) in mid-September.



ADVANCE® Knee System Awarded Registration in China

On August 4, MicroPort Orthopedics' ADVANCE® Knee System Cementless was permitted to register on the China market by China Food and Drug Administration.

The ADVANCE® Knee System was launched in the US market in 1998 and is proved to be safe and effective with its over 15 years' excellent clinical history. One of the star products is the ADVANCE® Medial-Pivot Knee, which was designed specifically to replicate normal knee motion by bending, rotating and twisting - all with a high degree of stability and range of motion. It was also designed with instrumentation that allows it to be used with a surgeon's minimally-invasive technique, which enables the patient to rehabilitate faster with less pain and return to his or her active lifestyle more quickly. Another benefit of the ADVANCE® Medial-Pivot Knee design is that it wears much less on the polyethylene (plastic insert) surface than other competitive knees, a result of its conformity (surface contact area).



Firehawk®
Rapamycin
Target Eluting
Coronary Stent
System


MicroPort Promotes Firehawk® in TCT 2014

MicroPort attended the 26th Transcatheter Cardiovascular Therapeutics ("TCT") held from September 13 to September 17 in Washington DC, to further promote its third-generation Drug Eluting Stent ("DES") Firehawk®.

During TCT, the world's largest educational meeting specializing in interventional cardiovascular medicine, MicroPort rebroadcasted two operations in which Firehawk® was used to treat left main bifurcation lesions, a cardiovascular disease. Meanwhile, Beijing-based Fuwai Hospital's Vice President Yuejin Yang and Professor Shubin Qiao were invited to introduce the advantages of Firehawk®. Participants can also learn about the main features of the world's only Target Eluting Stent through watching videos.

"We have spent eight years on research and development to make Firehawk® the lowest drug dosage DES in the world," said Qiyi Luo, Chief Technology Officer of MicroPort Scientific Corporation ("MPSC"). "After launched in China, Firehawk® has helped in improving life quality of many Chinese patients. We hope to take this opportunity of TCT to bring this revolutionary product to the international market to help more patients around the world."

MicroPort Completes First Human Implantation of its Transcatheter Aortic Valve



MicroPort successfully completed the first clinical trial of implanting its in-house developed artificial aortic heart valve in Shanghai Zhongshan Hospital on September 24.

The aortic valve was implanted using a revolutionary interventional procedure that doesn't need to open the patient's chest. The procedure, called Transcatheter Aortic Valve Replacement ("TAVR"), works in a similar way of heart stent implantation – the interventional cardiologist uses a catheter to deliver a collapsible valve to heart and makes the new valve expand to take over the job of regulating blood flow.

With less pain and faster recovery, TAVR could bring better experience for patients in most cases. For patients who are too sick or too old for conventional operations, it could mean a life-saving opportunity. However, currently the patients in China can't receive TAVR, because there is no approved transcatheter valve in Chinese market now.

In that case, MicroPort's high-quality and affordable valve is expected to allow more Chinese patients to enjoy the benefits of TAVR. Its self-expanding transcatheter aortic valve is designed to have better coaxial, anchoring and crossing ability, and most importantly it can reduce perivalvular leak. It is also easier to use with motorized handle.

"I believe MicroPort's domestically made valve could reduce the cost of the treatment and promote the use of TAVR," said Junbo Ge, Director of Cardiology in Shanghai Zhongshan Hospital. He noted, with an aging population, China will see more people suffer from aortic valve diseases and need the treatment of TAVR. It is estimated that there are 1 million elderly patients with the disease in the country.

"With our valve, MicroPort hopes to promote the development in clinical application of TAVR so as to benefit more patients in China," said Qiyi Luo, Chief Technology Officer of MPSC. "The first successful implantation also marks that MicroPort's research and development ability has reached a new level."

MicroPort will continue its clinical trial of the independently developed Transcatheter Aortic Valve in leading hospitals across China in the next two or three years to ensure its safety and efficacy.

Investor Newsletter

Issue **09** 2014



For more information, please contact:

Hongbin Sun

Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com

Xun You

Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com